Madrigal Pharmaceuticals (MDGL) Operating Income Growth (5y) (2015 - 2026)
Analysis
Madrigal Pharmaceuticals (MDGL) Operating Income Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 14.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83% |
| Mar 31, 2026 | -11.85% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -14.16% |
| Jun 30, 2025 | 1.27% |
| Mar 31, 2025 | -15.85% |
| Dec 31, 2024 | -17.47% |
| Sep 30, 2024 | -36.89% |
| Jun 30, 2024 | -48.24% |
| Mar 31, 2024 | -53.03% |
| Dec 31, 2023 | -51.97% |
| Sep 30, 2023 | -54.12% |
| Jun 30, 2023 | -61.68% |
| Mar 31, 2023 | -61.78% |
| Dec 31, 2022 | -57.11% |
| Sep 30, 2022 | -56.24% |
| Jun 30, 2022 | -52.79% |
| Mar 31, 2022 | -56.80% |
| Dec 31, 2021 | -52.80% |
| Sep 30, 2021 | -34.99% |